Berberine Fights Diabetic Heart Disease by Clearing Toxic Fat Droplets
New research reveals how berberine protects the heart in diabetes by activating cellular cleanup of harmful fat accumulation.
20 articles
New research reveals how berberine protects the heart in diabetes by activating cellular cleanup of harmful fat accumulation.
A post hoc analysis of the CLEAR Outcomes trial finds bempedoic acid significantly reduces DVT and pulmonary embolism risk.
Natural isoflavone prevents cardiac enlargement through novel mitochondrial protection pathway, offering new therapeutic approach.
Phase 3 trial of IBI306, a PCSK9 inhibitor, tests LDL-C reduction in Chinese adults with high cardiovascular risk on statin therapy.
Isolinderalactone from Lindera aggregata root reduces atherosclerotic plaques by targeting key inflammatory pathways in immune cells.
Small trial explores how amiloride improves oxygen delivery to heart muscle by enhancing potassium transport in red blood cells.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
A Phase 1/2 trial tests whether nicotinamide riboside can restore NAD+ balance and improve heart function in systolic HF patients.
Isoquercitrin reshapes gut bacteria and tryptophan metabolism to reduce arterial plaque, pointing to a novel gut-heart therapeutic pathway.
New study shows clearing senescent cells with Navitoclax improves heart function and reduces inflammation in heart failure with preserved ejection fraction.
New research reveals finerenone may reduce new-onset atrial fibrillation in heart failure patients with preserved ejection fraction.
TREM-1 inhibitor LR12 reduced harmful plaque formation in stents by nearly 50% without affecting healing in rabbit studies.
The first disease-specific treatment for Barth syndrome gains FDA accelerated approval, targeting mitochondrial dysfunction to restore muscle strength.
Zodasiran shows promise for patients with severe inherited cholesterol disorder, offering hope beyond traditional treatments.
Large study shows minocycline, an affordable antibiotic, significantly improved functional outcomes in stroke patients within 90 days.
The PRAISE-MR trial finds sacubitril/valsartan significantly improves exercise hemodynamics and quality of life in a high-risk HFpEF phenotype.
Clinical trial shows memantine reduces premature atrial contractions by 47% and prevents atrial fibrillation in heart patients.
Not all fibrates work the same way โ fenofibrate uniquely reduces apoB, cutting residual cardiovascular risk beyond statins alone.
A comprehensive GeneReviews update on Barth syndrome outlines diagnosis, new targeted therapy, and surveillance strategies for this rare X-linked disorder.
New review examines how elevated uric acid contributes to cardiovascular disease through inflammation and oxidative stress mechanisms.